Practice Essentials

Immunotherapy in Hodgkin Lymphoma: Current and Future Approaches to Treatment
Immunotherapy in Hodgkin Lymphoma: Current and Future Approaches to Treatment
CME, CPE
Anas Younes, MD
Release Date: August 06, 2018
Expiration Date: August 06, 2019
PD-1/PD-L1 inhibitors are a novel group of immune checkpoint inhibitors that can be used to treat patients with relapsed/refractory classical Hodgkin lymphoma (cHL). This activity will review the rationale for targeting PD-1/PD-L1 and summarize data on the activity and safety profile of PD-1/PD-LI inhibitors in the treatment of relapsed/refractory cHL. It will also review ongoing prospective trials assessing combination therapy with brentuximab vedotin and future directions in cHL treatment.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics, Inc.
Begin, Earn CreditView Only, No Credit
 
Practical Application of PET-Adapted Therapy in Hodgkin Lymphoma
Practical Application of PET-Adapted Therapy in Hodgkin Lymphoma
CME, CPE
Matthew Matasar, MD
Release Date: February 28, 2018
Expiration Date: February 28, 2019
The utilization of interim positron emission tomography (PET) imaging to guide therapeutic decisions has the potential to further individualize therapy, avoid unnecessary treatment and associated toxicity, and optimize outcomes for patients with Hodgkin lymphoma (HL). In this activity, participants will learn about the different PET-adapted strategies being investigated in HL, with a focus on the interpretation of data for the practical use of interim PET, to help providers evaluate the current clinical evidence and applicability to their practice.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Merck & Co., Inc., Seattle Genetics, and Takeda Oncology.
Begin, Earn CreditView Only, No Credit
 
The Future Impact of Novel Therapies on the Frontline Treatment of Hodgkin Lymphoma
The Future Impact of Novel Therapies on the Frontline Treatment of Hodgkin Lymphoma
CME, CPE
Stephen M. Ansell, MD, PhD
Release Date: October 19, 2017
Expiration Date: October 19, 2018
There are a number of investigational therapies and drug combinations being studied in the frontline treatment of patients with Hodgkin lymphoma (HL), including brentuximab vedotin (BV) in combination with immunotherapy, namely nivolumab, or various chemotherapy regimens. Health care providers must be aware of the potential impact of these new therapies on existing treatment paradigms and the standard of care in newly diagnosed HL. In this activity, participants will learn about the various investigational therapies and treatment strategies being studied in the frontline treatment of HL, as well as hear from expert faculty on the interpretation of the data and its relevance for clinical practice.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Merck & Co., Inc., Seattle Genetics, and Takeda Oncology.
Begin, Earn CreditView Only, No Credit
 
 Navigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma
Navigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma
CME, CPE
John Sweetenham, MD, FRCP, FACP
Release Date: August 23, 2017
Expiration Date: August 23, 2018
In this activity, participants will learn about treatment strategies and algorithms for selecting therapy in patients with relapsed and refractory Hodgkin lymphoma from Dr. John Sweetenham, who will also address the role of patient- and disease-related factors in treatment decisions, such as preexisting comorbidities, tolerability, and response to prior therapy.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Merck & Co., Inc., Seattle Genetics, and Takeda Oncology.
Begin, Earn CreditView Only, No Credit
 
Incorporating Immunotherapy in the Treatment of Hodgkin Lymphoma
Incorporating Immunotherapy in the Treatment of Hodgkin Lymphoma
CME, CPE
Craig Moskowitz, MD
Release Date: May 19, 2017
Expiration Date: May 19, 2018
The approval of nivolumab in May of 2016 for patients with classical Hodgkin lymphoma (HL) that has relapsed or progressed after autologous stem cell transplant and post-transplantation brentuximab vedotin, represented the first checkpoint inhibitor in HL. The unique features of checkpoint inhibitors, including immune-mediated adverse events and the possibility of non-traditional response patterns, may create a challenge in using these agents in practice. In this activity, Dr. Moskowitz will discuss the clinical profiles of recently approved immunotherapeutic agents, as they relate to HL, focusing on practical strategies for treatment and management of patients in practice, as well as on the safety and efficacy profiles of each.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Merck & Co., Inc., Seattle Genetics, and Takeda Oncology.
View Only, CE ExpiredView Only, No Credit
 

Managing HL would like to recognize and thank Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics for their educational support of ManagingHodgkinLymphoma.com in 2018.

©2018 MediCom Worldwide, Inc. All rights reserved